New Daily Weight Loss Pill Could Rival Ozempic With Impressive Trial Results

A new weight loss medication currently being trialed as a once-daily pill is showing tremendous promise—and it might soon compete directly with popular injectable drugs like Ozempic.

An estimated one in eight Americans have tried GLP-1 receptor agonist medications such as Ozempic, primarily prescribed for managing type 2 diabetes. While effective, these drugs can come with unpleasant side effects like nausea, fatigue, and digestive discomfort.

It's worth noting that Ozempic itself isn’t FDA-approved for weight loss, even though it’s widely used off-label for that purpose. However, other GLP-1-based medications, including semaglutide (Wegovy) and liraglutide (Saxenda), are officially approved for treating obesity.

Now, Eli Lilly, a pharmaceutical giant, may have made a breakthrough that changes the game entirely. They’ve developed Orforglipron, an experimental drug that belongs to the GLP-1 receptor agonist class but comes in the form of a simple pill.

Unlike injectable options like Ozempic, Orforglipron is taken orally once a day—without the need for food or even water, according to Verywell Health. That makes it significantly more convenient than alternatives like Rybelsus, the current GLP-1 pill on the market, which requires strict timing around meals and can cause significant nausea in some users.

What really has scientists and medical professionals excited, though, are the early clinical trial results.

In a 40-week study, Orforglipron was shown to reduce participants' A1C levels—a critical marker of long-term blood sugar control—by up to 1.6%. Even more impressive: among those on the highest dose (36 mg), nearly two-thirds achieved blood sugar levels below the threshold for diabetes.

And it doesn’t stop there.

Participants on the highest dose also lost an average of 8% of their body weight, or around 16 pounds. Remarkably, this weight loss occurred before the participants had even reached a plateau, meaning further reductions may have been possible had the trial continued beyond 40 weeks.

Another major advantage? Convenience. With Orforglipron, users can skip the weekly injections, potentially making treatment adherence easier and less invasive.

Side effects so far have been mild, mostly limited to gastrointestinal discomfort—a common issue across the GLP-1 drug class. More importantly, Orforglipron has shown no signs of liver toxicity, a serious concern that led Pfizer to pull the plug on its own GLP-1 pill candidate.

So what’s next?

Eli Lilly is aiming to secure FDA approval for Orforglipron as a weight-loss treatment later this year. Approval for diabetes treatment is projected to follow by 2026.

If approved, Orforglipron could become a market-shifting alternative to injectables like Ozempic and Wegovy, offering the same benefits with a much simpler and more user-friendly approach.

With rising obesity rates and millions seeking more accessible treatment options, this could be the pill that changes everything.

Is this the beginning of a new era in weight management?

It certainly looks that way.